Table 2.
Final pharmacokinetic and pharmacodynamic model parameters
| Parameter | Estimate | RSE+, CV% |
|---|---|---|
| VPQ, l (70 kg) | 130 | 6.05 |
| CLH1, l/h (70 kg) | 25.1 | 8.78 |
| CLH2, l/h (70 kg) | 5.6 | 29.6 |
| MAT, h | 0.915 | 11.2 |
| IIV CL#, CV% | 46 | 30.6 |
| IIV VPQ, CV% | 44 | 26.5 |
| IIV MAT, CV% | 55 | 28.8 |
| Proportional error, % | 25.3 | 20.0 |
| Additive error, ng/mla | 2 | – |
| Lifespan, h | 276 | 50 |
| Slope, CCYP2D6−1·h−1 | 0.0012 | 49 |
| FG6PDd | 2.46 | 103 |
| Proportional error Hb, V% | 6.95 | 4 |
CCYP2D6: concentration in the compartment for CYP2D6-mediated metabolites; CLH1: hepatic clearance out of the system; CLH2: CYP2D6-mediated hepatic clearance; CV: coefficient of variation; FG6PDd: factor by which the primaquine-induced elimination of erythrocytes is increased in G6PD-deficient individuals; IIV: inter-individual variability; MAT: mean absorption time; RSE: relative standard error; Slope: concentration-slope effect of primaquine-induced elimination of erythrocytes; VPQ: volume of distribution for primaquine
+As derived from a non-parametric bootstrap with 1000 samples
#Both CLH1 and CLH2 share the same inter-individual variability
aParameter was fixed during parameter estimation